• High levels of Lp(a) may contribute to the residual cardiovascular risk in statin-treated dyslipidemic patients.
Introduction
An elevated plasma lipoprotein(a) [Lp(a)] level is an established independent risk factor for cardiovascular disease (CVD) [1] [2] [3] [4] . High levels of Lp(a) may contribute to the considerable residual cardiovascular risk in statin-treated dyslipidemic patients including those with familial hypercholesterolemia (FH) with LDL-cholesterol below target levels [5, 6] . Lp(a) is an LDL-like particle with an apolipoprotein(a) [apo (a)] covalently attached to apolipoprotein B100. Lp(a) levels are highly genetically determined by the number of kringle IV (KIV) copies in the LPA gene encoding apo(a) [7] [8] [9] [10] [11] [12] . Five-to ten-fold higher plasma Lp(a) levels are found in individuals with at least one low molecular weight (LMW) apo(a) (≤22 KIV repeats) than in individuals only with high molecular weight (HMW) apo(a) (≥23 KIV repeats) [13] . Several single nucleotide polymorphisms (SNPs) in the LPA gene are strongly associated with Lp(a) levels and CVD [11, 12, 14, 15] . Although to a limited extent, non-genetic factors can affect Lp(a) plasma levels, such as for example weight reduction [16] , high saturated fat intake [17, 18] or kidney impairment [19] . Whether statins modify Lp(a) levels is not clear as inconsistent data have been reported [20] [21] [22] . Moreover, the underlying mechanisms remain to be clarified [21] [22] [23] . We hypothesized that the effect of statin treatment on Lp(a) levels depends on the KIV copy number and/or sequence variations in the LPA gene [24] .
To investigate the effect of statin treatment on plasma Lp(a) levels we determined changes in Lp(a) levels over time in dyslipidemic patients during the first few months after initiation of statin therapy. As a control we measured plasma Lp(a) levels at two distinct time points in dyslipidemic patients who were on stable statin treatment for at least 4 months. Secondly, we examined whether changes in plasma Lp(a) level induced by statin treatment were associated with apo(a) phenotype, common SNPs in the LPA gene and change in LDL cholesterol level.
Materials and methods

Study population
Patients aged ≥18 years were consecutively (2011) (2012) (2013) (2014) (2015) recruited at the outpatient cardiovascular genetics clinic at the Erasmus MC, Rotterdam, the Netherlands. The two study groups both consisted of patients with dyslipidemia, mostly (~85%) familial hypercholesterolemia (FH), and were primarily of Caucasian origin. In the initiation group, patients started statin treatment for the first time (n = 39), whereas in the control group patients were on stable statin treatment for at least 4 months (n = 42). Patients from the initiation group were newly referred to our tertiary center whereas patients from the control group were already seen at the outpatient clinic for follow up.
Fasting blood samples were obtained from each patient at 2 different time points with an interval of at least 2 months. In the initiation group the first time point was immediately before the initiation of statin treatment. Patients included in the control group did not change statin type or dose or use of other lipid-lowering drugs between the two blood sampling time points.
All participants provided written informed consent for blood collection and analysis, sample storage, and usage of biometrical data. This study was approved by the medical ethical committee of the Erasmus MC.
Anthropometric and laboratory measurements
Patient characteristics were recorded at baseline. Whole blood and plasma samples were stored at −80°C until further analysis. Total cholesterol, LDL-and HDL-cholesterol (LDL-C, HDL-C), triglycerides (TG) and apoB100 were measured using standard laboratory techniques. 'True LDL-C' was determined by subtracting Lp(a)-cholesterol from LDL-C. Lp(a)-cholesterol was calculated from the Lp(a) levels in nmol/L with the assumptions that the molecular cholesterol-toapoB100 ratio, and hence the cholesterol-to-apo(a) ratio, is similar to that of LDL, and that LDL consists of 25% apoB100 protein en 50% cholesterol by weight, as described by Viney et al. [25] .
Plasma Lp(a) levels (mg/dL or nmol/L) were measured with a particle-enhanced immunoturbidimetric assay, which is largely independent of apo(a) kringle IV (KIV) type 2 copy number (Diagnostic System #171399910930; DiaSys Diagnostic System, GmbH, Germany) [26] . Baseline and follow-up samples of all participants were measured in the same run and both samples were close to each other on the plate. The detection limit of the assay was 3.0 mg/dL and the mean intraassay variability was 2.8%. Sampling at two different time points in 28 healthy controls with an interval of 2-4 months did not reveal significant changes in Lp(a) level [27] . At baseline, the number of apo(a) KIV repeats was determined by SDS agarose gel electrophoresis and immunoblotting, as previously described [26] . When two apo(a) isoforms were identified in the blot, either the number of KIV repeats of the smallest isoform or the mean repeat number of both isoforms was used in the analysis. According to the number of KIV repeats, patients were classified as having an LMW apo(a) phenotype when they expressed at least one apo(a) isoform with ≤22 KIV repeats, or HMW apo (a) phenotype when they expressed only apo(a) isoforms with ≥23 KIV repeats.
DNA was isolated using the Invisorb ® Blood Universal Kit from Stratec Molecular (Berlin, Germany). Common variants of the LPA gene (rs10455872, rs3798220 and rs41272110 (T3888P)) [15, 28] were genotyped with TaqMan allelic discrimination assays, designed and optimized by Applied Biosystems (Foster City, CA, USA) on a Taqman Prism 7900 HT platform.
Statistical analysis
Normality of the data was tested with Shapiro-Wilks test. Differences between the intervention and the control group at baseline were tested using χ 2 tests with continuity correction, independent samples t tests or
Mann-Whitney U tests, according to the distribution of the data. The difference in Lp(a) level within the groups was analysed using Wilcoxon signed ranks tests. The relationship between change in Lp(a) level over time and apo(a) KIV repeat number was analysed with Spearman's rank order correlation test. Results with p values of < 0.05 were considered statistically significant. SPSS version 24.0 (IBM corp., Armonk, New York, USA) and GraphPad Prism version 5 (GraphPad Software, La Jolla, California, USA) were used for the statistical analyses. Table 1 shows the patient characteristics at baseline. The initiation group was younger and had higher baseline levels of total cholesterol, LDL-C and apoB100 than the control group. The median interval between the two blood sampling time points was 3.8 months (range 2-20 months) in the initiation group and 11.7 months (range 4-26 months) in the control group.
Results
Patient characteristics
Lipoprotein (a) levels
At baseline, median Lp(a) levels were 20.5 (IQR 10.9-80.7) mg/dL for the initiation group and 30.9 (IQR 9.2-147.0) mg/dL for the control group (Mann-Whitney U (MWU) = 702.5; Z = −1.101; p = 0.27). At the second time point, the median Lp(a) level of the initiation group was 23.3 (IQR 10.8-71.8) mg/dL, and 31.7 (IQR 10.9-164.0) mg/dL for the control group (MWU = 705.0; Z = −1.078; p = 0.28), which corresponds to a relative change of 13.7% (Wilcoxon Z = 1.697; p = 0.09) and 2.6% (Z = 0.518;p = 0.61), respectively. We found no difference between the two groups in the change of Lp(a) levels (MWU = 729.0; Z = −0.851; p = 0.40).
Association with apo(a) phenotypes
In both the initiation and control group, 14 patients (36% and 33%, respectively) had LMW apo(a) phenotype (χ 
Association with common LPA SNPs
In the combined initiation and control group, carriers of the minor rs10455872 allele had a higher Lp(a) level at baseline than non-carriers 
Association with LDL-cholesterol
In the initiation group, LDL-C levels decreased from 5.3 (IQR 4.4-6.4) to 3.1 (IQR 2.6-4.1) mmol/L (Z = 5.373; p < 0.001) on statin therapy. In the control group, LDL-C remained stable between the two time points (2.6 (IQR 2.2-2.9) mmol/L vs 2.7 (IQR 2.2-3.1) mmol/L (Z = 1.277; p = 0.202)). Qualitatively similar results were found for 'true LDL-C' levels, which were derived from LDL-C by correcting for Lp (a)-cholesterol. We found no association of LDL-C or 'true LDL-C' and Lp (a) at baseline in the initiation group (rho = −0.109; p = 0.52 and rho = −0.293; p = 0.074, respectively). In the control group, LDL-C was not associated with Lp(a) levels at baseline (rho = −0.014; p = 0.93) but 'true LDL-C' did (rho = −0.600; p < 0.001). In both groups, there was no association between change in Lp(a) and change in LDL-C in both groups (rho = −0.030; p = 0.86 and rho = −0.015; p = 0.93, respectively), nor with 'true LDL-C' (rho = −0.136; p = 0.39 and rho = −0.092; p = 0.58, respectively).
Discussion
Our data suggest that initiation of statin treatment increases Lp(a) levels in patients with dyslipidemia, but exclusively in patients with the LMW apo(a) phenotype. Initiation of statin treatment increased Lp(a) levels by 11.1% in the entire group, which is in line with results of two recent meta-analyses, showing an increase of 10.6% [29] and 4.14 mg/dL [30] . This average increase in our patients was mainly driven by the presence of an LMW apo(a) phenotype in whom the increase of Lp(a) level was roughly almost 50%. We did not find an interaction between Lp(a) change and common LPA SNPs across the groups, which may have been due to the low number of minor allele carriers in our study population. A recent meta-analysis of seven randomized controlled statin trials with cardiovascular disease outcomes showed no overall effect of 1-year statintreatment on plasma Lp(a) levels [31] , as Lp(a) levels significantly increased in 3 trials but decreased in 3 other trials. Compared to those trials, our study included predominantly familial hypercholesterolemia patients with relatively high baseline Lp(a) levels, who were statin treated for shorter time. Moreover, we were able to correlate changes in Lp(a) levels with the number of apo(a) KIV repeats, not only when used as a categorical but also as a continuous variable in the analysis. Lp(a) levels increased to a lesser extent with higher KIV repeat number, which was independent of baseline levels. To our knowledge, we are the first to show that the effect of statin treatment on plasma Lp(a) levels in individual patients depends on the apo(a) phenotype, with Lp(a) levels increasing exclusively in carriers of at least one apo(a) isoform with ≤22 KIV repeats.
The mechanism of this statin-induced increase in Lp(a) level remains unclear. The diagnosis of dyslipidemia and initiation of a statin could hypothetically have led to increased risk awareness, resulting in a change in lifestyle including for example less saturated fat-intake. Reduced fat intake and a shift from dietary saturated to unsaturated fat have been previously associated with increased Lp(a) levels [17] . Lp(a) levels increased more upon shift to dietary unsaturated fat in subjects with high baseline Lp(a) [18] , and hence presumably in subjects with LMW apo(a) phenotype than with HMW apo(a) phenotype. Alternatively, statins may indirectly increase plasma Lp(a) levels by upregulation of apo(a) synthesis or reducing Lp(a) clearance. Since smaller apo(a) isoforms with lower number of KIV repeats are secreted more efficiently and are cleared less efficiently than larger apo(a) isoforms [32] [33] [34] [35] , the statin effect may be more pronounced in subjects with LMW than the HMW apo(a) phenotype.
We found that 'true LDL-C' negatively associated with Lp(a) levels in patients from the control group, which are stably on statin treatment, but this did not reach statistical significance for patients in the initiation group at baseline, when not on cholesterol-lowering medication yet. The higher the levels of apo(a), the more apo(a) may become bound to LDL particles, thus explaining the negative association between 'true LDL-C' and Lp(a). That this reached statistically significant levels in the control group only may indicate some degree of overcorrection for Lp(a)-cholesterol, which will have a stronger effect after than before LDL-C is lowered by statin treatment.
It has long been known that statin treatment affects Lp(a) levels not in parallel with the lowering of LDL-C. Here, we show that statins even increase Lp(a) levels while lowering LDL. In addition, we found LDL-C and 'true LDL-C' levels not to be associated with Lp(a) levels over time after starting statin treatment. In contrast, monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9) have been shown to reduce Lp(a) levels in parallel with the lowering of LDL-C and apoB100 [36, 37] .Recently, Watts et al. [38] showed that PCSK9 inhibitors lower Lp(a) levels in healthy individuals by reducing the production of Lp(a)-associated apo(a), whereas it increases the clearance of Lp(a) when LDL-receptor expression is further upregulated by statin treatment, The mechanism underlying the upregulation of Lp(a) levels upon treatment of FH patients with a statin remains to be established.
Strenghts and limitations of the study
Limitations of this study are the small number of subjects included, the various types and dosages of statins and duration of treatment, the lack of data on lifestyle (in particular diet), and the observational nature of the study lacking randomization. Although we found no significant difference in baseline Lp(a) levels between the initiation and the control group, the Lp(a) level in the LMW group was higher in the control vs initiation group. Patients with high Lp(a) levels may be overrepresented in our control group of dyslipidemia patients who are frequently invited back at the outpatient clinic of our tertiary center despite being on stable statin treatment. However, this did not affect the main outcome. Strengths of this study include Lp(a) measurements of all samples in a single run and without repeated freezing-thawing cycles, the inclusion of a control group with constant statin treatment and the determination of the apo(a) phenotypes and common Lp(a) SNPs.
Conclusions
Our data shows that statin treatment increases Lp(a) levels in dyslipidemic patients with the LMW apo(a) phenotype. This increase was not associated with common LPA SNPs or change in LDL cholesterol. To understand the effects of statins and other drugs on Lp(a) levels, more research is needed on Lp(a) metabolism, including synthesis, clearance and turnover of apo(a).
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